Middle East Healthcare News

Hawaii Biotech Receives Allowance To Perform West Nile Vaccine Clinical Trials

September 22, 2017

Hawaii Biotech, Inc. announced that it has been notified by the United States Food and Drug Administration (FDA) that it may proceed to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine. The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding to complete the trial. Depending on the actual start date, results...

New Findings Highlight The Role Of Endothelial Cell Activation In Children With Cerebral Malaria

September 21, 2017

Researchers have identified a novel pathway that may contribute to the high mortality associated with severe malaria in sub-Saharan African children. The study, published March 20 in the open-access journal PLoS Pathogens, reports that severe Plasmodium falciparum infection results in disruption of the endothelium, causing release of ultra-large von Willebrand factor (VWF) protein. Together with reduced levels of VWF-specific cleaving enzyme ADAMTS13, this finding may contribute to our kno...

FDA Approves Quark IND For DGFi, An SiRNA Therapeutic Based On Silence Therapeutics' Unique Proprietary Chemistry

September 20, 2017

Silence Therapeutics plc (London AIM: SLN) announces that the U.S. Food and Drug Administration (FDA) has approved a Quark Pharmaceuticals Inc ("Quark") Investigational New Drug application (IND) for an siRNA therapeutic product based on Silence's unique proprietary chemistry. The product, DGFi, was discovered and is being developed by Quark for use in kidney transplantation. Rights to the AtuRNAi structure of DGFi were licensed to Quark by Silence Therapeutics. DGFi is being investigated for t...

New Measures For Bone Disease Developed By Doctors

September 19, 2017

As we age we can expect to shrink an average of three to four centimeters. Such loss is normal due to shrinkage of the disks within the spine. However, researchers at the University of Alberta have developed a guide to help doctors determine when height loss is a normal part of aging, and when it is likely due to something else--usually osteoporosis. And the guide could not be simpler to follow. Dr. Kerry Siminoski, an endocrinologist with the U of A and the Capital Health Authority, said doc...

Ferumoxytol Resubmission Designated Complete, Class 1 Response By FDA - Iron Deficiency Anemia In Chronic Kidney Disease Patients

September 18, 2017

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's resubmission to the October 2008 Complete Response letter for its New Drug Application (NDA) for ferumoxytol as a complete, Class 1 response. The FDA has established a December 30, 2008 Prescription Drug User Fee Act (PDUFA) target action date. AMAG is seeking marketing approval for ferumoxytol for the treatment of iron deficiency anemia in patients with all stag...